These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 26734984

  • 1. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study.
    Han M, Jiang J, Hou J, Tan D, Sun Y, Zhao M, Ning Q.
    Antivir Ther; 2016; 21(4):337-44. PubMed ID: 26734984
    [Abstract] [Full Text] [Related]

  • 2. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 3. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [Abstract] [Full Text] [Related]

  • 4. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT, Ye XG, Zhou XY.
    World J Gastroenterol; 2016 Dec 14; 22(46):10210-10218. PubMed ID: 28028369
    [Abstract] [Full Text] [Related]

  • 5. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.
    J Hepatol; 2014 Oct 14; 61(4):777-84. PubMed ID: 24915612
    [Abstract] [Full Text] [Related]

  • 6. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul 14; 21(7):502-5. PubMed ID: 24074707
    [Abstract] [Full Text] [Related]

  • 7. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.
    Antivir Ther; 2015 Jul 14; 20(2):217-24. PubMed ID: 25138110
    [Abstract] [Full Text] [Related]

  • 8. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD, Chen XF, Zhou Y, Chen XP.
    J Viral Hepat; 2017 Nov 14; 24 Suppl 1():36-42. PubMed ID: 29082651
    [Abstract] [Full Text] [Related]

  • 9. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ, Zoutendijk R, Hansen BE, Janssen HL.
    Antivir Ther; 2012 Nov 14; 17(8):1605-8. PubMed ID: 22898565
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L, Cariti G, Di Perri G, D'Avolio A.
    J Med Virol; 2016 Nov 14; 88(11):1953-9. PubMed ID: 27017932
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P.
    J Clin Virol; 2013 Dec 14; 58(4):713-7. PubMed ID: 24183313
    [Abstract] [Full Text] [Related]

  • 15. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Dec 14; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 16. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.
    Antivir Ther; 2013 Dec 14; 18(4):623-33. PubMed ID: 23486701
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy.
    Zhang XQ, Zhang HY, You JP, Mao Q.
    Virol J; 2013 Jan 15; 10():21. PubMed ID: 23320822
    [Abstract] [Full Text] [Related]

  • 18. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
    Xie Q, Zhou H, Bai X, Wu S, Chen JJ, Sheng J, Xie Y, Chen C, Chan HL, Zhao M.
    Clin Infect Dis; 2014 Dec 15; 59(12):1714-23. PubMed ID: 25190434
    [Abstract] [Full Text] [Related]

  • 19. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W, Wu D, Wang X, Chen T, Lai Q, Zheng Q, Jiang J, Hou J, Han M, Ning Q.
    Antivir Ther; 2015 Dec 15; 20(6):591-602. PubMed ID: 25814467
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
    Luo XD, Chen XP, Chen R, Chen XF, Huang J.
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr 15; 24(4):241-5. PubMed ID: 27470620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.